在实验性心力衰竭中固酶-5和-9的联合抑制
Miriam T Rademaker1, Nicola J A Scott1, Christopher J Charles1
1Christchurch Heart Institute, Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand.
JACC. Heart failure
|November 3, 2023
概括
固酶PDE5和PDE9的双抑制可以提高心力衰竭中循环氨单酸盐 (cGMP) 的水平. 组合疗法改善了心血管和功能,支持其作为心力衰竭治疗的潜力.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
- 脏生理学 脏生理学
背景情况:
- 循环氨酸单酸盐 (cGMP) 是一个重要的第二信使,调节循环平衡和心血管保护.
- 抑制固酶 (PDEs) PDE5和PDE9代表了心力衰竭 (HF) 的一个有前途的治疗途径.
研究的目的:
- 在实验性心力衰竭中研究PDE5和PDE9联合抑制对cGMP水平和心血管参数的影响.
- 为了评估与单一治疗相比,双重PDE抑制的协同或添加效应.
主要方法:
- 八只患有节奏诱导心力衰竭的羊接受了静脉注射PDE5抑制剂 (西尔德纳菲尔),PDE9抑制剂 (PF-04749982),组合或车辆控制.
- 血液动力学参数 (平均动脉压,左心房压,肺动脉压),肺血管阻力和尿路标志物 (cGMP,肌,体积,) 被测量.
主要成果:
- 抑制PDE5和PDE9都会增加循环中的cGMP,降低心血管压力,抑制PDE5对cGMP和血液动力学产生更大的影响.
- 与单一治疗相比,组合疗法进一步降低了平均动脉压,左心房压和肺动脉压.
- 虽然这两种抑制剂都增加了尿液中的cGMP,但只有PDE9抑制和组合疗法诱导了显著的尿路和自然尿路,其效应与PDE9单一治疗相当.
结论:
- 联合PDE5和PDE9抑制协同增强cGMP信号传递,将PDE5抑制的肺功效与PDE9抑制的功效合并.
- 这种双重抑制策略有效地减少了心脏前负荷和后负荷,为心力衰竭管理提供了一种可行的治疗方法.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.5K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:26Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
01:22Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346